8 results on '"Wingate, Heather"'
Search Results
2. Birth Outcomes Among People with Hepatitis C in Pregnancy — Three U.S. States, 2018–2021.
- Author
-
Woodworth, Kate R., Newton, Suzanne M., Tannis, Ayzsa, Reynolds, Megan R., Olsen, Emily O., Sizemore, Lindsey, Wingate, Heather, Orkis, Lauren, Reynolds, Bethany, Longcore, Nicole, Thomas, Nadia, Kim, Shin Y., Panagiotakopoulos, Lakshmi, Wester, Carolyn, Delman, Dana Meaney, Gilboa, Suzanne M., and Tong, Van T.
- Subjects
HEPATITIS C diagnosis ,SUBSTANCE abuse ,PUBLIC health surveillance ,SMALL for gestational age ,NEONATAL abstinence syndrome ,RESEARCH funding ,PREMATURE infants ,PREGNANCY outcomes ,PREGNANT women ,ATTITUDES of mothers ,NEONATAL intensive care ,DESCRIPTIVE statistics ,PREGNANCY complications ,HEPATITIS C ,DATA analysis software ,CONFIDENCE intervals ,DISEASE risk factors ,DISEASE complications ,PREGNANCY - Abstract
Introduction: There are limited and conflicting data regarding the impact of hepatitis C in pregnancy on adverse birth outcomes. Methods: Using the Surveillance for Emerging Threats to Pregnant People and Infants Network (SET-NET), a large surveillance cohort, we describe birth outcomes among a cohort of people with HCV in pregnancy in total and by reported substance use. Results: Among 1418 infants, 89% were born to people with reported substance use during pregnancy. The proportion born preterm was 20%, 13% were small-for-gestational age and 34% of term infants required intensive care. Conclusions: Assessments of recent changes to recommendations for HCV screening in pregnancy should evaluate the impact on maternal access to care for both HCV treatment as well as comorbidities such as substance use disorder which may contribute to adverse birth outcomes. Significance: Incidence of hepatitis C in pregnancy is increasing. Prematurity, small-for-gestational age, and intensive care unit admission were common among this surveillance cohort of infants born to people with hepatitis C in pregnancy with high frequency of substance use. Assessments of recent changes to recommendations for HCV screening in pregnancy should evaluate the impact on maternal access to care for both HCV treatment as well as comorbidities such as substance use disorder which may contribute to adverse birth outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Pregnancy and infant outcomes by trimester of SARS‐CoV‐2 infection in pregnancy–SET‐NET, 22 jurisdictions, January 25, 2020–December 31, 2020.
- Author
-
Neelam, Varsha, Reeves, Emily L., Woodworth, Kate R., O'Malley Olsen, Emily, Reynolds, Megan R., Rende, Joy, Wingate, Heather, Manning, Susan E., Romitti, Paul, Ojo, Kristen D., Silcox, Kristin, Barton, Jerusha, Mobley, Evan, Longcore, Nicole D., Sokale, Ayomide, Lush, Mamie, Delgado‐Lopez, Camille, Diedhiou, Abdoulaye, Mbotha, Deborah, and Simon, Wanda
- Abstract
Objectives: We describe clinical characteristics, pregnancy, and infant outcomes in pregnant people with laboratory‐confirmed SARS‐CoV‐2 infection by trimester of infection. Study Design: We analyzed data from the Surveillance for Emerging Threats to Mothers and Babies Network and included people with infection in 2020, with known timing of infection and pregnancy outcome. Outcomes are described by trimester of infection. Pregnancy outcomes included live birth and pregnancy loss (<20 weeks and ≥20 weeks gestation). Infant outcomes included preterm birth (<37 weeks gestation), small for gestational age, birth defects, and neonatal intensive care unit admission. Adjusted prevalence ratios (aPR) were calculated for pregnancy and selected infant outcomes by trimester of infection, controlling for demographics. Results: Of 35,200 people included in this analysis, 50.8% of pregnant people had infection in the third trimester, 30.8% in the second, and 18.3% in the first. Third trimester infection was associated with a higher frequency of preterm birth compared to first or second trimester infection combined (17.8% vs. 11.8%; aPR 1.44 95% CI: 1.35–1.54). Prevalence of birth defects was 553.4/10,000 live births, with no difference by trimester of infection. Conclusions: There were no signals for increased birth defects among infants in this population relative to national baseline estimates, regardless of timing of infection. However, the prevalence of preterm birth in people with SARS‐CoV‐2 infection in pregnancy in our analysis was higher relative to national baseline data (10.0–10.2%), particularly among people with third trimester infection. Consequences of COVID‐19 during pregnancy support recommended COVID‐19 prevention strategies, including vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Risk factors for illness severity among pregnant women with confirmed SARS-CoV-2 infection – Surveillance for Emerging Threats to Mothers and Babies Network, 22 state, local, and territorial health departments, March 29, 2020 -March 5, 2021
- Author
-
Galang, Romeo R, Newton, Suzanne M, Woodworth, Kate R, Griffin, Isabel, Oduyebo, Titilope, Sancken, Christina L, Olsen, Emily O'Malley, Aveni, Kathryn, Wingate, Heather, Shephard, Hanna, Fussman, Chris, Alaali, Zahra S, Silcox, Kristin, Siebman, Samantha, Halai, Umme-Aiman, Lopez, Camille Delgado, Lush, Mamie, Sokale, Ayomide, Barton, Jerusha, Chaudhary, Ifrah, Patrick, Paul H, Schlosser, Levi, Reynolds, Bethany, Gaarenstroom, Nicole, Chicchelly, Sarah, Read, Jennifer S, de Wilde, Leah, Mbotha, Deborah, Azziz-Baumgartner, Eduardo, Hall, Aron J, Tong, Van T, Ellington, Sascha, and Gilboa, Suzanne M
- Subjects
Adult ,SARS-CoV-2 ,COVID-19 ,Mothers ,macromolecular substances ,AcademicSubjects/MED00290 ,illness severity ,Pregnancy ,Risk Factors ,Humans ,Supplement Article ,Female ,Pregnant Women ,Pregnancy Complications, Infectious ,Aged - Abstract
Background Pregnant women with coronavirus disease 2019 (COVID-19) are at increased risk for severe illness compared with nonpregnant women. Data to assess risk factors for illness severity among pregnant women with COVID-19 are limited. This study aimed to determine risk factors associated with COVID-19 illness severity among pregnant women with SARS-CoV-2 infection. Methods Pregnant women with SARS-CoV-2 infection confirmed by molecular testing were reported during March 29, 2020–March 5, 2021 through the Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET). Criteria for illness severity (asymptomatic, mild, moderate-to-severe, or critical) were adapted from National Institutes of Health and World Health Organization criteria. Crude and adjusted risk ratios for moderate-to-severe or critical COVID-19 illness were calculated for selected demographic and clinical characteristics. Results Among 7,950 pregnant women with SARS-CoV-2 infection, moderate-to-severe or critical COVID-19 illness was associated with age 25 years and older, healthcare occupation, pre-pregnancy obesity, chronic lung disease, chronic hypertension, and pregestational diabetes mellitus. Risk of moderate-to-severe or critical illness increased with the number of underlying medical or pregnancy-related conditions. Conclusions Older age and having underlying medical conditions were associated with increased risk of moderate-to-severe or critical COVID-19 illness among pregnant women. This information might help pregnant women understand their risk for moderate-to-severe or critical COVID-19 illness and inform targeted public health messaging.
- Published
- 2021
5. Using Public Health Surveillance Data to Determine Hepatitis C Virus Exposure Among Live-Born Infants in Tennessee, 2013-2017.
- Author
-
Wingate, Heather, Sizemore, Lindsey, Black, Jennifer, Heth, Zachary, Talley, Pamela, Patrick, Stephen W., and Wester, Carolyn
- Subjects
- *
HEPATITIS C transmission , *PUBLIC health surveillance , *MOTHERS , *PUBLIC health , *HEPATITIS viruses , *MOTHER-infant relationship , *LONGITUDINAL method - Abstract
Objective: Maternal hepatitis C virus (HCV) infection reported on birth certificates has been shown to underestimate HCV infection. We sought to determine the usefulness of HCV surveillance data for (1) quantifying the number of HCV-positive reproductive-aged women with a live birth, (2) comparing maternal HCV surveillance data with reported HCV infection status on birth certificates, and (3) delineating past versus current maternal infection to identify true perinatal exposures. Methods: We extracted data from January 1, 2013, through December 31, 2017, on birth certificate indication of HCV exposure from the Tennessee Birth Statistical File, and we ascertained indication of HCV exposure by using laboratory data from the Tennessee National Electronic Disease Surveillance System (NEDSS) Base System (NBS). We conducted a sensitivity analysis comparing birth certificate indication of HCV exposure with HCV laboratory data to determine whether true perinatal exposure had occurred. Results: During the study period, 6731 mothers with live births in Tennessee reported having HCV infection during pregnancy: 3295 (49.0%) had both laboratory and birth certificate indication of HCV infection, 2130 (31.6%) had indication of HCV infection on the laboratory report only, and 1306 (19.4%) had indication of HCV infection on the birth certificate only. Conclusions: Using data from a public health HCV surveillance system with birth certificate data may improve the identification of HCV-infected pregnant women and perinatally exposed infants. Surveillance systems that include complete reporting of all HCV RNA results can be used to distinguish past from present maternal HCV infection to focus limited public health resources on currently infected mothers and their exposed infants. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Risk Factors for Illness Severity Among Pregnant Women With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 Infection—Surveillance for Emerging Threats to Mothers and Babies Network, 22 State, Local, and Territorial Health Departments, 29 March 2020–5 March 2021
- Author
-
Galang, Romeo R, Newton, Suzanne M, Woodworth, Kate R, Griffin, Isabel, Oduyebo, Titilope, Sancken, Christina L, Olsen, Emily O'Malley, Aveni, Kathryn, Wingate, Heather, Shephard, Hanna, Fussman, Chris, Alaali, Zahra S, Silcox, Kristin, Siebman, Samantha, Halai, Umme-Aiman, Lopez, Camille Delgado, Lush, Mamie, Sokale, Ayomide, Barton, Jerusha, and Chaudhary, Ifrah
- Subjects
PUBLIC health surveillance ,COVID-19 ,CONFIDENCE intervals ,SEVERITY of illness index ,RISK assessment ,DESCRIPTIVE statistics ,DATA analysis software ,WOMEN'S health ,EVALUATION ,PREGNANCY - Abstract
Background Pregnant women with coronavirus disease 2019 (COVID-19) are at increased risk for severe illness compared with nonpregnant women. Data to assess risk factors for illness severity among pregnant women with COVID-19 are limited. This study aimed to determine risk factors associated with COVID-19 illness severity among pregnant women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods Pregnant women with SARS-CoV-2 infection confirmed by molecular testing were reported during 29 March 2020–5 March 2021 through the Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET). Criteria for illness severity (asymptomatic, mild, moderate-to-severe, or critical) were adapted from National Institutes of Health and World Health Organization criteria. Crude and adjusted risk ratios for moderate-to-severe or critical COVID-19 illness were calculated for selected demographic and clinical characteristics. Results Among 7950 pregnant women with SARS-CoV-2 infection, moderate-to-severe or critical COVID-19 illness was associated with age 25 years and older, healthcare occupation, prepregnancy obesity, chronic lung disease, chronic hypertension, and pregestational diabetes mellitus. Risk of moderate-to-severe or critical illness increased with the number of underlying medical or pregnancy-related conditions. Conclusions Older age and having underlying medical conditions were associated with increased risk of moderate-to-severe or critical COVID-19 illness among pregnant women. This information might help pregnant women understand their risk for moderate-to-severe or critical COVID-19 illness and can inform targeted public health messaging. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. SARS-CoV-2 During Omicron Variant Predominance Among Infants Born to People With SARS-CoV-2.
- Author
-
Gosdin, Lucas, Chang, Daniel, O'Malley Olsen, Emily, Lewis, Elizabeth L., Wingate, Heather, Ojo, Kristen D., Shephard, Hanna, Sokale, Ayomide, Mobley, Evan L., Delgado-López, Camille, Hall, Aron J., Gilboa, Suzanne M., Van T. Tong, and Woodworth, Kate R.
- Subjects
- *
MATERNAL exposure , *COVID-19 , *GENETIC mutation , *CONFIDENCE intervals , *DISEASE duration , *RESEARCH funding , *DESCRIPTIVE statistics , *POLYMERASE chain reaction , *COVID-19 testing , *STATISTICAL sampling , *PREGNANCY , *CHILDREN - Abstract
The article presents a study which examined the rates of SARS-CoV-2 infection before and during the period of Omicron variant predominance among infants born to people with infection during pregnancy and whether the period of maternal infection affects infant susceptibility. Topics discussed include background on the evolution of SARS-CoV-2, analysis of the timing of positive tests, and incidence rate of positive SARS-CoV-2 testing among infants born to people with SARS-CoV-2 infection.
- Published
- 2023
- Full Text
- View/download PDF
8. Timing of Positive Hepatitis C Virus Test Results During and 1 Year Before Pregnancy.
- Author
-
Woodworth, Kate R., Newton, Suzanne M., Olsen, Emily O., Tannis, Ayzsa, Sizemore, Lindsey, Wingate, Heather, Orkis, Lauren, Reynolds, Bethany, Longcore, Nicole, Thomas, Nadia, Bocour, Angelica, Wills, Aprielle, Kim, Shin Y., Panagiotakopoulos, Lakshmi, Wester, Carolyn, Delman Meaney, Dana, Gilboa, Suzanne M., and Tong, Van T.
- Subjects
- *
HEPATITIS C virus , *HEPATITIS C , *PREGNANCY - Abstract
The incidence of hepatitis C virus (HCV) infection in reproductive-aged adults quadrupled during the past decade. Hepatitis C can progress to advanced liver disease and be transmitted perinatally. Highly effective curative hepatitis C treatment is available but is not recommended in pregnancy. Using the Surveillance for Emerging Threats to Mothers and Babies Network, we describe timing of positive RNA testing among pregnant people with HCV (HCV RNA detected during or within one year prior to pregnancy). Four US jurisdictions reported 1161 pregnancies during 2018-2021 among people with hepatitis C: 75.9% were multiparous; and 21.4% had their first peri-pregnancy HCV RNA detected prior to pregnancy, indicating potential missed treatment opportunities to improve maternal health and prevent perinatal transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.